Advertisement

Osteoporosis

  • Nese Yuksel
  • Theresa L. CharroisEmail author
Chapter

Abstract

Osteoporosis is a chronic condition related to low bone mass that can lead to an increased risk of fracture. Pharmacists play a role in identifying patients at risk of osteoporosis and optimizing therapy for those patients on osteoporosis medications. Ensuring patients are on appropriate medications, and are able to adhere to them, is an integral part of the management of osteoporosis. Long-term follow-up including assessment of fractures is key in determining efficacy. Pharmacists can use a multi-faceted approach to determine effectiveness and safety with these medications, as well as determine when it is appropriate to have patients take a drug holiday from these medications.

Keywords

Osteoporosis Bisphosphonates Risk assessment 

References

  1. 1.
    International Osteoporosis Foundation. https://www.iofbonehealth.org/osteoporosis. Accessed Apr 2018.
  2. 2.
    Ioannidis G, Papaioannou A, Hopman WM, Akhtar-Danesh N, Anastassiades T, Pickard L, et al. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ. 2009;181(5):265–71.CrossRefGoogle Scholar
  3. 3.
    Colon-Emeric C, Kuchibhatla M, Pieper C, Hawkes W, Fredman L, Magaziner J, et al. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int. 2003;14(11):879–83.CrossRefGoogle Scholar
  4. 4.
    Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–81.CrossRefGoogle Scholar
  5. 5.
    Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int. 2009;20(10):1633–50.CrossRefGoogle Scholar
  6. 6.
    Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010;182(17):1864–73.CrossRefGoogle Scholar
  7. 7.
    Yuksel N, Majumdar SR, Biggs C, Tsuyuki RT. Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial. Osteoporos Int. 2010;21(3):391–8.CrossRefGoogle Scholar
  8. 8.
    Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, et al. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician. 2014;60:324–33.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.University of Alberta, Faculty of Pharmacy and Pharmaceutical SciencesEdmontonCanada

Personalised recommendations